• Je něco špatně v tomto záznamu ?

Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?

V Soukup, M Babjuk, J Duskova, M Pesl, M Szakaczova, L Zamecnik, J Dvoracek

. 2008 ; 80 (4) : 413-418.

Jazyk angličtina Země Švýcarsko

Typ dokumentu randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc11004110

Grantová podpora
NR8934 MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Článek
Zdroj

E-zdroje

NLK Karger Journals od 1955 do 2009
Medline Complete (EBSCOhost) od 1998-01-01 do Před 1 rokem

INTRODUCTION: To evaluate the prognostic value of T1 subclassification and fascin-1 expression in T1 human urothelial cell carcinoma of the bladder. MATERIALS AND METHODS: In a prospective study with 105 consecutive patients, T1 tumors were subclassified into 2 groups according to the depth of tumor invasion. The tunica muscularis mucosae was used as a landmark. The expression of fascin-1 was examined by using an anti-fascin-1 mouse monoclonal antibody and was evaluated semiquantitatively for both intensity and distribution. The patients were followed up for 27.3 +/- 13.7 months. RESULTS: The T1 tumor subclassification was feasible in 99 patients (94%). T1a tumor was detected in 77 patients (73%), T1b tumor in 22 patients (21%). An invasive tumor was found in 5 patients (4.8%) during the restaging transurethral resection of the bladder. The risk of understaging in patients with T1b tumor was 18%. There was not a significant difference in time to the recurrence in the T1a and the T1b group. The progression-free survival rates were significantly different between both groups (p = 0.0034). No correlation was found between fascin-1 positivity and the depth of tumor invasion. Fascin-1 positivity did not correlate with recurrence or the progression-free intervals. In the multivariate analysis, only the extent of lamina propria invasion was an independent predictor of the tumor progression. The fascin positivity was not an independent prognostic factor relating to the risk of recurrence or progression. CONCLUSION: The finding of T1b tumor was connected with a significantly higher risk of progression and understaging. The fascin-1 expression did not correlate with the depth of tumor invasion or with the tumor recurrence or progression. 2008 S. Karger AG, Basel.

000      
02849naa 2200697 a 4500
001      
bmc11004110
003      
CZ-PrNML
005      
20140225132555.0
008      
110303s2008 sz e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Soukup, Viktor, $d 1974- $7 xx0081956
245    10
$a Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma? / $c V Soukup, M Babjuk, J Duskova, M Pesl, M Szakaczova, L Zamecnik, J Dvoracek
314    __
$a Department of Urology, General Teaching Hospital, 1st Medical Faculty, Charles University, Prague, Czech Republic. viktor.soukup@centrum.cz
520    9_
$a INTRODUCTION: To evaluate the prognostic value of T1 subclassification and fascin-1 expression in T1 human urothelial cell carcinoma of the bladder. MATERIALS AND METHODS: In a prospective study with 105 consecutive patients, T1 tumors were subclassified into 2 groups according to the depth of tumor invasion. The tunica muscularis mucosae was used as a landmark. The expression of fascin-1 was examined by using an anti-fascin-1 mouse monoclonal antibody and was evaluated semiquantitatively for both intensity and distribution. The patients were followed up for 27.3 +/- 13.7 months. RESULTS: The T1 tumor subclassification was feasible in 99 patients (94%). T1a tumor was detected in 77 patients (73%), T1b tumor in 22 patients (21%). An invasive tumor was found in 5 patients (4.8%) during the restaging transurethral resection of the bladder. The risk of understaging in patients with T1b tumor was 18%. There was not a significant difference in time to the recurrence in the T1a and the T1b group. The progression-free survival rates were significantly different between both groups (p = 0.0034). No correlation was found between fascin-1 positivity and the depth of tumor invasion. Fascin-1 positivity did not correlate with recurrence or the progression-free intervals. In the multivariate analysis, only the extent of lamina propria invasion was an independent predictor of the tumor progression. The fascin positivity was not an independent prognostic factor relating to the risk of recurrence or progression. CONCLUSION: The finding of T1b tumor was connected with a significantly higher risk of progression and understaging. The fascin-1 expression did not correlate with the depth of tumor invasion or with the tumor recurrence or progression. 2008 S. Karger AG, Basel.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a karcinom z přechodných buněk $x genetika $x metabolismus $x mortalita $x patologie $7 D002295
650    _2
$a transportní proteiny $x genetika $x metabolismus $7 D002352
650    _2
$a interval spolehlivosti $7 D016001
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikrofilamentové proteiny $x genetika $x metabolismus $7 D008840
650    _2
$a lidé středního věku $7 D008875
650    _2
$a invazivní růst nádoru $x genetika $x patologie $7 D009361
650    _2
$a lokální recidiva nádoru $x genetika $x mortalita $7 D009364
650    _2
$a staging nádorů $7 D009367
650    _2
$a odds ratio $7 D016017
650    _2
$a prognóza $7 D011379
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a prospektivní studie $7 D011446
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a analýza přežití $7 D016019
650    _2
$a nádorové biomarkery $x analýza $x genetika $7 D014408
650    _2
$a nádory močového měchýře $x genetika $x metabolismus $x mortalita $x patologie $7 D001749
650    _2
$a financování organizované $7 D005381
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Babjuk, Marko, $d 1961- $7 jn20020716353
700    1_
$a Dušková, Jaroslava, $d 1952- $7 jo2002104714
700    1_
$a Pešl, Michal, $d 1975- $7 xx0081957
700    1_
$a Szakácsová, Monika, $d 1981- $7 xx0104837
700    1_
$a Zámečník, Libor, $d 1970- $7 ola2003209167
700    1_
$a Dvořáček, Jan, $d 1943- $7 jn19981000912
773    0_
$t Urologia Internationalis $w MED00004616 $g Roč. 80, č. 4 (2008), s. 413-418
910    __
$a ABA008 $b x $y 1 $z 0
990    __
$a 20110414092507 $b ABA008
991    __
$a 20140225133406 $b ABA008
999    __
$a ok $b bmc $g 831449 $s 696138
BAS    __
$a 3
BMC    __
$a 2008 $b 80 $c 4 $d 413-418 $m Urologia internationalis $n Urol Int $x MED00004616
GRA    __
$a NR8934 $p MZ0
LZP    __
$a 2011-3B/ipme

Najít záznam